Related Experiment Video
Updated: Jun 9, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
Published on: September 22, 2011
The developability classification system: application of biopharmaceutics concepts to formulation development
James M Butler1, Jennifer B Dressman
1Pharmaceutical Development, GlaxoSmithKline R&D, Harlow, UK. james.m.butler@gsk.com
Abstract:
A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the in vivo performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to in vivo performance than the widely used BCS.
Related Concept Videos
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Release Testing: Overview, Development and Validation
Preclinical Development: Overview
